Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

NCT07150403 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Carcinoma (mCRC)

Interventions

DRUG: Oxaliplatin intravenous
DRUG: 5 FU bolus
DRUG: Folinic acid
DRUG: 5 FU continuous
DRUG: Irinotecan
DRUG: FRUQUINTINIB
DRUG: BEVACIZUMAB

Sponsor

Federation Francophone de Cancerologie Digestive